Phase I/II trial of cilengitide with cetuximab, cisplatin and 5-fluorouracil in recurrent and/or metastatic squamous cell cancer of the head and neck: findings of the phase I part.
about
The physiology of cardiovascular disease and innovative liposomal platforms for therapyRGD-Binding Integrins in Head and Neck Cancers.Mechanism and efficacy of sub-50-nm tenfibgen nanocapsules for cancer cell-directed delivery of anti-CK2 RNAi to primary and metastatic squamous cell carcinoma.Cilengitide inhibits attachment and invasion of malignant pleural mesothelioma cells through antagonism of integrins αvβ3 and αvβ5.Antiangiogenic therapy for glioma.Role of intratumoural heterogeneity in cancer drug resistance: molecular and clinical perspectivesSystemic therapy strategies for head-neck carcinomas: Current statusThe role of PET/CT in cervical cancerCombining molecular targeted agents with radiation therapy for malignant gliomasFocal adhesion complex proteins in epidermis and squamous cell carcinoma.Cisplatin, 5-fluorouracil, and cetuximab (PFE) with or without cilengitide in recurrent/metastatic squamous cell carcinoma of the head and neck: results of the randomized phase I/II ADVANTAGE trial (phase II part).Current treatment options for recurrent/metastatic head and neck cancer: a post-ASCO 2011 update and review of last year's literature.Angiogenesis inhibitors in cancer therapy: mechanistic perspective on classification and treatment rationales.Angiogenesis in cancer: Anti-VEGF escape mechanismsThe effect of cilengitide in combination with irradiation and chemotherapy in head and neck squamous cell carcinoma cell lines.Reduced Cytokine Release in Ex Vivo Response to Cilengitide and Cetuximab Is a Marker for Improved Survival of Head and Neck Cancer PatientsOsteopontin-integrin α(v)β(3) axis is crucial for 5-fluorouracil resistance in oral squamous cell carcinoma.Biologic therapy in head and neck cancer: a road with hurdles.Feasibility of 6-month maintenance cetuximab after adjuvant concurrent chemoradiation plus cetuximab in squamous cell carcinoma of the head and neck.Phase Ib trial of the Toll-like receptor 9 agonist IMO-2055 in combination with 5-fluorouracil, cisplatin, and cetuximab as first-line palliative treatment in patients with recurrent/metastatic squamous cell carcinoma of the head and neck.[Immunotherapy of head and neck cancer. Current developments].Antigen-specific immunotherapy in head and neck cancer
P2860
Q27002949-039B9233-197A-42A3-B1C5-1A2BB5D29A39Q33832735-DE09672C-5AEC-4E3B-9D2A-4477B6C8A4EEQ34020978-0BB61C57-DCD0-4EC5-A96F-9A489D84A13CQ35111316-BF68045C-9BA4-4747-A868-E22879046BB8Q36101999-19857399-A7E5-46E3-A28B-D7D08BCEB0BFQ36386428-56B346CE-D200-42C2-AF75-5990AFC674FEQ36529843-D298763D-C43F-4063-9C42-58A592575AB0Q36637204-DDE0EB9B-C329-48F4-96B4-B04F9A26F07FQ37099594-CAF0B234-9912-4F49-9B86-18226B521A6BQ37452962-DA6BA3F2-5FAB-48A0-8E1D-372C593BB6E3Q37600501-72F320A9-61FC-4E56-A95E-33AB679DF2F9Q37995872-3EE091CF-4913-41CE-A940-8657D3C2DF77Q38130312-98CA184B-B21D-42A6-A792-3C6E0C7278C7Q38389975-6CBC3C21-20F0-4409-8379-8656C0FCBC4DQ39021996-C7085A1E-3419-492E-B4A7-EF65ACED5F61Q41670908-BA312602-418B-41D4-9EE3-399E98AD0E15Q41702715-5A3530CA-80B1-439A-8D55-81ED4BD934E9Q42213295-57BFE75F-D19F-45D9-B949-FEFEA707CF6FQ43447566-31154C8C-C81A-4F48-9D82-852971A2AD27Q45732639-E33E96CB-A323-40BE-A83A-5A0F4D335D63Q45770749-8570ABC2-6151-45A6-9CFC-179E6EE09CDEQ58146388-836458D1-CFC8-4283-9859-D06B962F42AF
P2860
Phase I/II trial of cilengitide with cetuximab, cisplatin and 5-fluorouracil in recurrent and/or metastatic squamous cell cancer of the head and neck: findings of the phase I part.
description
2011 nî lūn-bûn
@nan
2011 թուականի Մայիսին հրատարակուած գիտական յօդուած
@hyw
2011 թվականի մայիսին հրատարակված գիտական հոդված
@hy
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
name
Phase I/II trial of cilengitid ...... findings of the phase I part.
@ast
Phase I/II trial of cilengitid ...... findings of the phase I part.
@en
type
label
Phase I/II trial of cilengitid ...... findings of the phase I part.
@ast
Phase I/II trial of cilengitid ...... findings of the phase I part.
@en
prefLabel
Phase I/II trial of cilengitid ...... findings of the phase I part.
@ast
Phase I/II trial of cilengitid ...... findings of the phase I part.
@en
P2093
P2860
P921
P356
P1476
Phase I/II trial of cilengitid ...... findings of the phase I part.
@en
P2093
J B Vermorken
T H Brummendorf
U Keilholz
P2860
P2888
P304
P356
10.1038/BJC.2011.152
P407
P577
2011-05-03T00:00:00Z